Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 36,922 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 36,922 shares of the company’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the sale, the chief financial officer directly owned 281,867 shares in the company, valued at approximately $7,300,355.30. The trade was a 11.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.83, for a total transaction of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.98, for a total value of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.77, for a total value of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total value of $275,092.78.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $31.01 on Tuesday. The business has a 50 day simple moving average of $19.95 and a 200 day simple moving average of $31.92. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The company has a market capitalization of $7.07 billion, a PE ratio of 60.80, a price-to-earnings-growth ratio of 2.74 and a beta of 2.32. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same period in the prior year, the business posted $0.11 earnings per share. The business’s revenue was up 28.4% compared to the same quarter last year. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.61 EPS for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the subject of several analyst reports. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Friday, March 27th. Truist Financial reiterated a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. BTIG Research lowered Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Finally, Leerink Partners raised their price target on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $31.86.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Investor momentum: Traders are buying HIMS on optimism about its peptide drug pipeline and reports of a potential deal with Novo Nordisk, which, coupled with an upcoming May 11 earnings report, is cited as the main catalyst for the rally. Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
• Neutral Sentiment: Biotech sector news: Positive clinical data at peers (e.g., Nektar’s alopecia results) is lifting sentiment across small-cap biopharma stocks; this sector-wide risk-on tone may be contributing to flows into HIMS even if the news isn’t company-specific. This Biotech Stock Soars on Hair Loss Trial Results. It Isn’t a Cure for Baldness.
• Neutral Sentiment: Short-interest update: A recent short-interest note was published; changes in short interest can amplify moves into earnings but the update itself doesn’t clearly favor one direction. Monitor short-interest levels for potential squeeze risk. Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Update
• Negative Sentiment: Insider sales: CFO Oluyemi Okupe sold a block of shares on Apr 16–17 (total ~54,927 shares) under a pre‑arranged Rule 10b5‑1 plan — roughly $1.46M at the reported prices — reducing his stake. The sales are disclosed in an SEC Form 4 filing; because they were executed under a 10b5‑1 plan the signal is muted but still a short‑term caution for sentiment. SEC Form 4 – Insider Sale

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Quent Capital LLC bought a new stake in shares of Hims & Hers Health during the third quarter valued at approximately $28,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health in the 3rd quarter worth approximately $28,000. Bogart Wealth LLC raised its position in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the 1st quarter worth $30,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.